7 Related NICE guidance
Details are correct at the time of publication. Further information is available on the NICE website.
Published
-
Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal 237). NICE technology appraisal guidance 274 (2013).
-
Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy. NICE technology appraisal guidance 271 (2013).
-
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 229 (2011).
-
Ranibizumab and pegaptanib for the treatment of age\u2011\related macular degeneration. NICE technology appraisal guidance 155 (2008).
Under development
-
Aflibercept solution for injection for the treatment of macular oedema caused by central retinal vein occlusion. NICE technology appraisal. Publication date to be confirmed.